Radiotherapy plus durvalumab in locally advanced NSCLC: the DOLPHIN study

被引：0
|
作者：
Trommer, Maike [1 ,2 ,3 ,4 ]
机构：
[1] Med Fak, Ctr Integrated Oncol Aachen Bonn Cologne Duesseldo, Klin & Poliklin Radioonkol Cyberknife & Strahlenth, Cologne, Germany
[2] Univ Klinikum Koln, Cologne, Germany
[3] Austin Hlth, Olivia Newton John Canc Wellness & Res Ctr, Dept Radiat Oncol, Melbourne, Australia
[4] Univ Klinikum Koln, Ctr Mol Med Cologne CMMC, Cologne, Germany
来源：
STRAHLENTHERAPIE UND ONKOLOGIE | 2024年 / 200卷 / 07期
关键词：
D O I：
10.1007/s00066-024-02231-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：646 / 648
页数：3
相关论文
共 50 条
  • [1] Phase II Study of Durvalumab Plus Concurrent Radiotherapy in Unresectable Locally Advanced NSCLC: DOLPHIN Study (WJOG11619L)
    Tachihara, M.
    Tsujino, K.
    Shimokawa, M.
    Ishihara, T.
    Hayashi, H.
    Sato, Y.
    Kurata, T.
    Sugawara, S.
    Shiraishi, Y.
    Teraoka, S.
    Azuma, K.
    Daga, H.
    Yamaguchi, M.
    Kodaira, T.
    Satouchi, M.
    Yamamoto, N.
    Nakagawa, K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S64 - S64
  • [2] Radiotherapie plus Durvalumab beim lokal fortgeschrittenen NSCLC: die DOLPHIN-StudieRadiotherapy plus durvalumab for the treatment of locally advanced non-small cell lung cancer—The DOLPHIN trial
    Maike Trommer
    [J]. Strahlentherapie und Onkologie, 2024, 200 (7) : 646 - 648
  • [3] Tremelimumab plus Durvalumab Prior to Chemoradiotherapy in Unresectable Locally Advanced NSCLC, the Induction Trial
    Smeenk, M. M.
    van Diessen, J. N. A.
    Boellaard, T. N.
    Hartemink, K. J.
    de Vries, J. F.
    Badrising, S. K.
    Wondergem, M.
    Wittenberg, R.
    Monkhorst, K.
    van den Heuvel, M. M.
    Theelen, W. S. M. E.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S157 - S157
  • [4] Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer The DOLPHIN Phase 2 Nonrandomized Controlled Trial
    Tachihara, Motoko
    Tsujino, Kayoko
    Ishihara, Takeaki
    Hayashi, Hidetoshi
    Sato, Yuki
    Kurata, Takayasu
    Sugawara, Shunichi
    Shiraishi, Yoshimasa
    Teraoka, Shunsuke
    Azuma, Koichi
    Daga, Haruko
    Yamaguchi, Masafumi
    Kodaira, Takeshi
    Satouchi, Miyako
    Shimokawa, Mototsugu
    Yamamoto, Nobuyuki
    Nakagawa, Kazuhiko
    [J]. JAMA ONCOLOGY, 2023, 9 (11) : 1505 - 1513
  • [5] Durvalumab after Radiochemotherapy for locally advanced unresectable NSCLC - a Breakthrough
    Guckenberger, Matthias
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (01) : 95 - 97
  • [6] Combination of radiotherapy and chemotherapy in locally advanced NSCLC
    Kepka, Lucyna
    Sprawka, Arkadiusz
    Casas, Francesc
    Abdel-Wahab, Sherif
    Agarwal, Jai Prakash
    Jeremic, Branislav
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (10) : 1389 - 1403
  • [7] Chemotherapy or radiotherapy for palliation of locally advanced NSCLC?
    Sundstrom, S.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2006, 81 : S4 - S4
  • [8] Radiotherapy with daily Taxol in locally advanced NSCLC
    Brodin, O
    Helsing, M
    Henriksson, R
    Wagenius, G
    [J]. LUNG CANCER, 2005, 49 : S277 - S277
  • [9] A phase I/II study of durvalumab and stereotactic radiotherapy in locally advanced pancreatic cancer
    Tuli, Richard
    Nissen, Nicholas
    Lo, Simon
    Tighiouart, Mourad
    Placencio, Veronica
    Hendifar, Andrew
    [J]. CANCER RESEARCH, 2019, 79 (24)
  • [10] A Phase I/II Study of durvalumab and stereotactic radiotherapy in locally advanced pancreatic cancer
    Tuli, R.
    Nisen, N.
    Lo, S.
    Placencio, V.
    Gresham, G.
    Hendifar, A.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S424 - S425
12345